Dendritic cell vaccines for the treatment of prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 576-580

  Lehrfeld, Todd J ^a   Lee, David I ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Advanced; Dendritic; Immunology; Immunotherapy; Metastatic; Prostate cancer; Provenge

Indexed keywords

DENDRITIC CELL VACCINE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TUMOR IMMUNOLOGY;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 55249114939     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.12.002     Document Type: Review

References (55)

1. Jamal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Jones G.W., Mettlin C., Murphy G.P., et al. Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Call Surg 180 (1995) 545-554
3. Stamey T.A., Yemoto C.M., McNeal J.E., et al. Prostate Cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 163 (2000) 1155-1160
4. Messing E.M., and Thompson Jr. I. Follow-up of conservatively managed prostate cancer: Watchful waiting and primary hormonal therapy. Urol Clin North Am 30 4 (2003) 687-702
5. Dillioglugil O., Leibman B.D., Kattan M.W., et al. Hazard rates for Progression after radical prostatectomy for clinically localized prostate cancer. Urology 50 (1997) 93-99
6. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
7. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3,283 deaths in 5,710 patients. Lancet 346 (1995) 265-269
8. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
9. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
10. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
11. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: A treatment for the masses. Science 305 (2004) 200-205
12. Nelson W.G., De Marzo A.M., De Weese T.L., et al. The role of inflammation in the pathogenesis of prostate cancer. J Urol 172 (2004) S6-S12
13. Pontari M.A., and Ruggieri M.R. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 172 (2004) 839-845
14. Pavlenko M., Roos A.K., Lundqvist A., et al. A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91 (2004) 688-694
15. Fong L., Brockstedt D., Benike C., et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167 (2001) 7150-7156
16. Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177 luteium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4569-4601
17. Miller A.M., and Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56 (2005) 81-87
18. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
19. Tjoa B.A., and Murphy G.P. Development of dendritic-cell based prostate cancer vaccine. Immunol Lett 74 (2000) 87-93
20. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
21. Mehta-Damani A., Markowicz S., and Engleman E.G. Generation of antigen-specific CD8+ CTLs from naïve precursors. J Immunol 153 (1994) 996-1003
22. Aalamian-Matheis M., Chatta G.S., Shurin M.R., et al. Inhibition of dendritic cell generation and function by serum from prostate cancer patients: Correlation with serum-free PSA (2007) 173-182 601
23. Banchereau J., and Palucka A.K. Dendritic Cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
24. Sporri R., and Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CDR+ T cell populations lacking helper function. Nat Immunol 6 (2005) 163-170
25. O' Neill D.W., Adams S., Bhardwaj N., et al. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104 (2004) 2235-2246
26. Gilboa E. The makings of a tumor rejection antigen. Immunity 11 (1999) 263-270
27. Van Tendeloo V.F., Ponsaerts P., Lardon F., et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98 (2001) 49-56
28. Nair S.K., Heiser A., Boczkowski D., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6 (2000) 1011-1017
29. Schmitz M., Diestelkoetter P., Weigle B., et al. Generation of surviving-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides (2000) 4845-4849 60
30. Hueman M.T., Dehqanzada Z.A., Novak T.E., et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 11 (2005) 7470-7479
31. Renneberg H., Friedetzky A., Konrad L., et al. Prostate specific membrane antigen (PSM) is expressed in various human tissues: Implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread. Urol Res 27 (1999) 23-27
32. Murphy G., Tjoa B., Ragde H., et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29 (1996) 371-380
33. Murphy G.P., Tjoa B.A., Simmons S.J., et al. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39 (1999) 54-59
34. Tjoa B.A., Erickson S.J., Bowes V.A., et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32 (1997) 272-278
35. Tjoa B.A., Simmons S.J., Bowes V.A., et al. Evaluation of Phase I-II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36 (1998) 39-44
36. Tjoa B.A., Simmons S.J., Elgamal A., et al. Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate 40 (1999) 125-129
37. Oesterling J.E. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145 (1991) 907-923
38. Papsidero L.D., Kuriyama M., Wang M.C., et al. Prostate antigen: A marker for human prostate epithelial cells. J Natl Cancer Inst 66 (1981) 37-42
39. Heiser A., Maurice M.A., Yancey D.R., et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166 (2001) 2953-2960
40. Heiser A., Coleman D., Dannull J., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109 (2002) 409-417
41. Barrou B., Benoit G., Ouldkaci M., et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53 (2004) 453-460
42. Perambakam S., Hallmeyer S., Reddy S., et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 55 (2006) 1033-1042
43. Waeckerle-Men Y., Uetz-von A.E., Fopp M., et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55 (2006) 1524-1533
44. Fuessel S., Meye A., Schmitz M., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a Phase I clinical trial. Prostate 66 (2006) 811-821
45. Thomas-Kaskel A.K., Zeiser R., Jochim R., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119 (2006) 2428-2434
46. Thomas-Kaskel A.K., Waller C.F., Schultze-Seemann W., et al. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 121 (2007) 467-473
47. Su Z., Yang B.K., Dahm P., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174 (2005) 3798-3807
48. Heller J.E. Prostatic acid phosphatase: Its current clinical status. J Urol 137 (1987) 1091-1103
49. Schellhammer P.F., and Hershberg R.M. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 23 (2005) 47-49
50. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded cells. J Clin Oncol 18 (2000) 3894-3903
51. Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6 (2000) 2175-2182
52. Burch P.A., Croghan G.A., Gastineaue D.A., et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase II trial. Prostate 60 (2004) 197-204
53. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
54. Lim A.M., Hershberg R.M., and Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 24 (2006) 434-441
55. PCA Immunotherapy may have benefits. Sipuleucel-T prolonged PSA doubling time in patients with androgen-dependent prostate cancer. Renal Urol News 31 (2007) Sept